Evidence map›Paper›PMID 32703743›Full record

ArticleVaccine2021

A global agenda for older adult immunization in the COVID-19 era: A roadmap for action.

Lois A Privor-Dumm, Gregory A Poland, Jane Barratt, David N Durrheim, Maria Deloria Knoll, Prarthana Vasudevan, Mark Jit, Pablo E Bonvehí, Paolo Bonanni, International Council on Adult Immunization

Open access · greenAbstract readConference Proceedings
In one paragraph

Article in Vaccine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 3 pooled it
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 83 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Observational
  15. Journal of preventive medicine and hygiene · 2024
    Article
  16. Review
  17. Review
  18. Review
  19. Status of Herpes Zoster and Herpes Zoster Vaccines in 2023: A position paper.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 5 countries.

Lois A Privor-DummInternational Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Gregory A PolandMayo Vaccine Research Group, Mayo Clinic and Foundation, Rochester, MN, USA.
Jane BarrattInternational Federation on Ageing, Toronto, Canada.
David N DurrheimPublic Health Medicine, University of Newcastle, Wallsend, NSW, Australia.
Maria Deloria KnollInternational Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Prarthana VasudevanInternational Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Mark JitDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, England, United Kingdom.
Pablo E BonvehíEMIC, Buenos Aires, Argentina.
Paolo BonanniDepartment of Health Sciences, University of Florence, Florence, Italy.
International Council on Adult Immunization
Johns Hopkins University · USInternational Federation on Ageing · CALondon School of Hygiene & Tropical Medicine · GBMayo Clinic · USUniversity of Florence · ITUniversity of Newcastle Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Given our global interconnectedness, the COVID-19 pandemic highlights the urgency of building a global system that can support both routine and pandemic/epidemic adult immunization. As such, a framework to recommend vaccines and build robust platforms to deliver them to protect the rapidly expanding demographic of older adults is needed. Adult immunization as a strategy has the broad potential to preserve and improve medical, social, and economic outcomes, including maintaining functional ability that benefits older adults, their families, communities, and countries. While we will soon have multiple vaccines against COVID-19, we must recognize that we already have a variety of vaccines against other pathogens that can keep adults healthier. They can prevent simultaneous co-infection with COVID-19, and may favorably impact- the outcome of a COVID-19 illness. Further, administering a vaccine against COVID-19 requires planning now to determine delivery strategies impacting how older adults will be immunized in a timely manner. A group of international experts with various backgrounds from health and aging disciplines met to discuss the evidence case for adult immunization and crucial knowledge gaps that must be filled in order to implement effective policies and programs for older adult immunization. This group, coming together as the International Council on Adult Immunization (ICAI), outlined a high-level roadmap to catalyze action, provide policy guidance, and envision a global adult immunization platform that can be adapted by countries to fit their local contexts. Further meetings centered around the value of adult immunization, particularly in the context of COVID-19. There was agreement that programs to deliver existing influenza, pneumococcal, herpes zoster vaccines, and future COVID-19 vaccines to over a billion older adults who are at substantially higher risk of death and disability due to vaccine-preventable diseases are more urgent than ever before. Here we present a proposed framework for delivering routine and pandemic vaccines. We call upon the global community and governments to prioritize action for integrating robust adult immunization programs into the public health agenda.

Indexed as

COVID-19Influenza VaccinesVaccinesAgedCOVID-19 VaccinesHumansImmunizationImmunization ProgramsPandemicsSARS-CoV-2VaccinationCOVID-19 VaccinesInfluenza VaccinesVaccinesAdult immunizationAgingCOVID-19Older adultsPolicyVaccines

Identifiers

PMID32703743
PMCPMC7332930
OpenAlexW3042345804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.